Immunotherapy

C. Ola Landgren and colleagues discuss adapting to a field transformed by new immunotherapy drugs and targeted therapies and how to best combine treatments

Revvity presented their diverse portfolio of cancer research tools at AACR, reaffirming their commitment to empowering researchers

Adding atezolizumab immunotherapy to postsurgery chemotherapy doesn’t have the same benefits as the pre-surgery regimen

Liquid biopsy helps screen for ctDNA, which is linked to how patients respond to immuno- and chemo-therapy ​

The FDA granted the approval of Amtagvi to Iovance Biotherapeutics Inc.

Phase 2 trial finds durvalumab–ceralasertib boosted immune response and improved outcomes in patients with lung cancer

Phase 2 trial suggests pre-surgical immunotherapy is safe and may be an effective option for patients with soft-tissue sarcomas

Venetoclax administered with bendamustine+rituximab as the first therapy for mantle cell lymphoma led to 85 percent complete response rate